secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2026-05-01T23:59:59+00:00
Accession:  0001682852-26-000057
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna Q1 2026 revenue $389M, GAAP net loss $(1.3)B including $0.9B litigation charge
--------------------------------------------------------------------------------

- Revenue $389M (+$281M YoY); ~80% from international; GAAP EPS $(3.40) vs $(2.52) YoY.
- Net loss $(1.3)B includes $0.9B non-recurring litigation settlement charge; cash $7.5B.
- Reaffirms up to 10% revenue growth in 2026; cost of sales guidance ~$1.8B including charge.
- EU approved mNEXSPIKE and mCOMBRIAX (flu+COVID combo); Phase 3 initiated for intismeran in NSCLC.
- R&D expenses down 24% YoY to $649M; SG&A down 18% to $173M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285226000057/0001682852-26-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285226000057/mrna-20260501.htm
  HTML page:      https://secwatch.observer/filing/0001682852-26-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer